Pfizer is developing an at-home pill against COVID-19

Pfizer is developing an at-home pill against COVID-19

The middle of the week came with news from one of the most popular pharma companies right now due to its COVID-19 vaccine – Pfizer

Pfizer, the company that developed the first authorized COVID- 19 vaccine in the US, announced that it began in March an early-stage clinical trial of a new medicine for the disease. The new drug is a protease inhibitor and works by inhibiting an enzyme that the virus needs to replicate in human cells. These types of inhibitors are already being used in treating HIV and hepatitis C.

According to Pfizer CEO Albert Bourla, if everything goes smoothly and the FDA approves the drug, it will hit the shelves by the end of the year.

From the health experts’ perspective, the ingestible drug could be a game-changer because infected people could use it outside hospitals.

Besides the news drug, Pfizer is testing its vaccine in 6-months to 11-year-old children, after the company received from the FDA the authorization to expand its vaccine usage to adolescents aged between 12 – 15.

The market seemed to react positively to the news. At the moment of writing, Pfizer stock price is trading 0.57% higher.

Sources: cnbc.com, finance.yahoo.com

The information presented herein is prepared by CAPEX.com and does not intend to constitute Investment Advice. The information herein is provided as a general marketing communication for information purposes only and as such it has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and it is not subject to any prohibition on dealing ahead of the dissemination of investment research.

Users/readers should not rely solely on the information presented herewith and should do their own research/analysis by also reading the actual underlying research. The content herewith is generic and does not take into consideration individual personal circumstances, investment experience or current financial situation.

Therefore, Key Way Investments Ltd shall not accept any responsibility for any losses of traders due to the use and the content of the information presented herein. Past performance is not a reliable indicator of future results.